Charles Haworth is a Respiratory Consultant working within the Cambridge Centre for Lung Infection at Royal Papworth Hospital where he specialises in treating adults with bronchiectasis, non-tuberculous mycobacterial (NTM) infections and cystic fibrosis.
He co-authored the British Thoracic Society Bronchiectasis clinical guidelines published in 2017 and the European Respiratory Society Bronchiectasis clinical guidelines published 2019.
He was also senior author of the International Cystic Fibrosis NTM guidelines published in 2015 and first author of the British Thoracic Society NTM guidelines published in 2017.
Between 2018-2021 he was a founding and executive committee member of the UK Cystic Fibrosis Medical Association.
In June 2024 he was invited to join the Board of the European Cystic Fibrosis Society.
- Lung infection
- Bronchiectasis
- Non-Tuberculous mycobacterial (NTM) infection
- Cystic fibrosis
Dr Charles Haworth is the clinical trials lead within the Cambridge Centre for Lung Infection at Royal Papworth Hospital and an affiliated associate professor at the University of Cambridge.
His research involves evaluating novel therapeutic approaches in patients with bronchiectasis, NTM-lung disease, and cystic fibrosis. He collaborates with Professor Andres Floto at the University of Cambridge on a variety of experimental medicine studies, he has been chief investigator of four international clinical trial programmes in bronchiectasis, and is a steering committee member of phase II / III medicinal trials currently being performed in the UK, Europe and North America.
He has received grant funding from the EU Horizon 2020 Programme (x2), National Institute of Health Research (x4) and Health Data Research UK. He is a Principal Investigator for the European Cystic Fibrosis Society Clinical Trials network and the UK Cystic Fibrosis Trust Clinical Trials Network. He is also member of the European Bronchiectasis Registry Scientific committee, the NIHR Cystic Fibrosis National Research Strategy Group, and the Cambridge Clinical Research Centre Scientific Advisory Board.
He was a member of the US Cystic Fibrosis Foundation Data Safety Monitoring Board 2011-2022.
1993 M.B.Ch.B. Manchester University
1996 M.R.C.P. London
2003 M.D. Manchester University
2003 CCST in Respiratory Medicine
2003 Respiratory Medicine Specialist Register
2007 F.R.C.P. London
Current roles:
- Consultant Respiratory Physician, Cambridge Centre for Lung Infection, Royal Papworth Hospital
- Affiliated Associate Professor, Department of Medicine, University of Cambridge
- Clinical Trials Lead, Cambridge Centre for Lung Infection, Royal Papworth Hospital
- Scientific Advisory Board, Cambridge Clinical Research Centre
- Board Member, European Cystic Fibrosis Society
Previous roles:
- Director, Cambridge Centre for Lung Infection, Royal Papworth Hospital 2007-2019
- Clinical Director Thoracic Medicine, Royal Papworth Hospital 2013-2016
Current memberships:
- Fellow of the Royal College of Physicians
- Member of the British Thoracic Society
- Member of the European Respiratory Society
- Member of the American Thoracic Society
- Member of the European Cystic Fibrosis Society
Chalmers JD et al. Phase 3 trial of the DPP1 inhibitor brensocatib in bronchiectasis. New Engl J Med. In press [co-author]
Haworth CS et al. Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, phase 3 trials assessing safety and efficacy over 12 months. Lancet Respir Med. 2024 [first author]
Morawska L, et al. Mandating indoor air quality for public buildings. Science 2024 [co-author]
Chalmers JD, et al. Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis Registry (EMBARC). Lancet Respir Med. 2023 [co-author]
Allen L, et al. Future therapies for cystic fibrosis. Nat Commun. 2023 [co-author]
Morawska L, et al. A paradigm shift to combat indoor respiratory infection. Science. 2021 [co-author]
Loebinger MR, et al. Efficacy and safety of TOBI Podhaler in Pseudomonas aeruginosa-infected bronchiectasis patients: iBEST study. Eur Respir J. 2021 [senior author]
Chalmers JD, Haworth CS, et al. Phase II trial of the DPP-1 inhibitor Brensocatib in bronchiectasis. New Engl J Med. 2020 [second author]
Haworth CS, et al. Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials. Lancet Respir Med. 2019 [first author]
Haworth CS, et al. British Thoracic Society Guidelines for the Management of Non-Tuberculous Mycobacterial Pulmonary Disease (NTM-PD). Thorax. 2017 [first author]
*Hill A, *Haworth CS, et al. Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. Eur Respir J. 2017 [*Joint first authors]
Polverino E, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017 [co-author]
Bryant JM, et al. Emergence and spread of a human- transmissible multidrug-resistant nontuberculous mycobacterium. Science 2016 [co-author]
Floto RA, et al. CF Foundation and European CF Society Consensus Recommendations for the management of nontuberculous in individuals with CF. Thorax 2016 [senior author]
Haworth CS, et al. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Resp Crit Care Med 2014 [first author]
Bryant JM, et al. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet 2013 [co-author]
